Cargando…
Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466112/ https://www.ncbi.nlm.nih.gov/pubmed/30577664 http://dx.doi.org/10.3390/biomedicines7010001 |
_version_ | 1783411034954924032 |
---|---|
author | Vallera, Daniel A. Kreitman, Robert J. |
author_facet | Vallera, Daniel A. Kreitman, Robert J. |
author_sort | Vallera, Daniel A. |
collection | PubMed |
description | Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue. |
format | Online Article Text |
id | pubmed-6466112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64661122019-04-19 Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity Vallera, Daniel A. Kreitman, Robert J. Biomedicines Review Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue. MDPI 2018-12-21 /pmc/articles/PMC6466112/ /pubmed/30577664 http://dx.doi.org/10.3390/biomedicines7010001 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vallera, Daniel A. Kreitman, Robert J. Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity |
title | Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity |
title_full | Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity |
title_fullStr | Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity |
title_full_unstemmed | Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity |
title_short | Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity |
title_sort | immunotoxins targeting b cell malignancy—progress and problems with immunogenicity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466112/ https://www.ncbi.nlm.nih.gov/pubmed/30577664 http://dx.doi.org/10.3390/biomedicines7010001 |
work_keys_str_mv | AT valleradaniela immunotoxinstargetingbcellmalignancyprogressandproblemswithimmunogenicity AT kreitmanrobertj immunotoxinstargetingbcellmalignancyprogressandproblemswithimmunogenicity |